The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL)

被引:40
|
作者
Bavi, Prashant [1 ]
Uddin, Shahab [1 ]
Bu, Rong [1 ]
Ahmed, Maqbool [1 ]
Abubaker, Jehad [1 ]
Balde, Valorie [1 ]
Qadri, Zeeshan [1 ]
Ajarim, Dahish [2 ]
Al-Dayel, Fouad [3 ]
Hussain, Azhar R. [1 ]
Al-Kuraya, Khawla S. [1 ]
机构
[1] King Faisal Specialist Hosp & Res Canc, Res Ctr, King Fahad Natl Ctr Childrens Canc, Riyadh 11211, Saudi Arabia
[2] King Faisal Canc Ctr, Riyadh, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Canc, Dept Pathol, Riyadh 11211, Saudi Arabia
来源
JOURNAL OF PATHOLOGY | 2011年 / 224卷 / 03期
关键词
DLBCL; NF-kappa B; NHL therapy; activated B cell (ABC) phenotype; apoptosis; XIAP; tissue microarray; TISSUE MICROARRAY ANALYSIS; PRIMARY EFFUSION LYMPHOMA; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; CANCER-THERAPY; SAUDI-ARABIA; PATHWAY; KINASE; ALPHA;
D O I
10.1002/path.2864
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
NF-kappa B is frequently over-expressed in a variety of non-Hodgkin's lymphomas (NHLs) and has been implicated in lymphomagenesis; however, its role in diffuse large B cell lymphoma (DLBCL) as a prognostic biomarker has not been fully elucidated. Therefore, we investigated the role of NF-kappa B and its association with clinicopathological features in a tissue microarray cohort of 230 DLBCL patient samples. We then elucidated the role of NF-kappa B inhibition on cell viability and apoptosis in vitro, using DLBCL cell lines. Using immunohistochemistry, NF-kappa B was detected in 25.6% (52/203) DLBCL tumours, was associated with activated B cell (ABC) phenotype (p = 0.0054), Epstein-Barr virus (EBV; p = 0.0080) and over-expression of the anti-apoptotic marker XIAP (p = 0.0013). DLBCL cases with nuclear expression of NF-kappa B showed a significantly poorer overall survival as compared to those without NF-kappa B expression (p = 0.0236). In a multivariate analysis using a Cox proportional hazard model for IPI and NF-kappa B expression, the relative risk was 2.97 for high NF-kappa B expression (95% CI 1.27-6.94; p = 0.0113) and 7.55 for the high-IPI group (95% CI 3.34-18.35; p < 0.0001). In vitro, Bay 11-7085 inhibited constitutively active NF-kappa B expression in a dose-dependent manner and inhibition of NF-kappa B also down-regulated expression of the downstream target gene products Bcl-2, Bcl-XL (BCL2L1), XIAP and Survivin, leading to apoptosis via activation of the mitochondrial apoptotic pathway. NF-kappa B over-expression was found to be an independent prognostic marker for poor survival in DLBCL. Altogether, these results suggest that NF-kappa B may be a useful prognostic biomarker and a potential target for therapeutic intervention in DLBCL. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:355 / 366
页数:12
相关论文
共 50 条
  • [31] Puffing the 'Activate' in Activated B Cell-like Diffuse Large B Cell Lymphoma: A Role for the Noncanonical NF-κB Pathway
    Koff, Jean L.
    Guo, Xiangxue
    Ramachandiran, Sampath
    Switchenko, Jeffrey M.
    Mosunjac, Marina B.
    Neill, Stewart G.
    Mann, Karen
    Bagirov, Mahir
    Flowers, Christopher R.
    Lossos, Izidore S.
    Natkunam, Yaso
    Kowalski, Jeanne
    Bernal-Mizrachi, Leon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S143 - S143
  • [32] RPRD1B/CREPT facilitates the progression of diffuse large B-cell lymphoma by inhibiting apoptosis through the NF-κB signaling pathway
    Xu, Lu
    Xie, Zhi-Hao
    Li, Jun
    Tao, Shi
    Ren, Fang-Li
    Wang, Yin-Yin
    Chang, Zhi-Jie
    Hao, Xin-Bao
    ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE, 2024, 14 (07) : 307 - 317
  • [33] The role of CNS prophylaxis in diffuse large B-cell lymphoma (DLBCL)
    Korfel, A.
    ONKOLOGIE, 2010, 33 : 26 - 27
  • [34] Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL)
    Talaulikar, D.
    Dahlstrom, J.
    Shadbolt, B.
    Broomfield, A.
    McDonald, A.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2008, 30 : 146 - 147
  • [35] Pharmacogenetic Approaches Identify ANTXR1 As a Potential Mediator of Response to Therapeutic NF-κB Inhibition in Diffuse Large B Cell Lymphoma
    Puvvada, Soham D.
    Love, Cassandra L.
    Grubor, Vladimir
    Zhang, Jenny
    Smith, Jason
    Dave, Sandeep S.
    BLOOD, 2011, 118 (21) : 107 - 107
  • [36] Outcomes of Patients with Transformed Diffuse Large B-Cell Lymphoma (DLBCL)
    Nakashima, J.
    Cruz-Chamarro, R.
    Laborde, J.
    Kim, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E479 - E479
  • [37] Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL)
    Talaulikar, Dipti
    Dahlstrom, Jane Esther
    Shadbolt, Bruce
    Broomfield, Amy
    McDonald, Anne
    JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2008, 56 (10) : 893 - 900
  • [38] Molecular insights into treatment failure in Diffuse Large B Cell Lymphoma (DLBCL)
    Alruwetei, Abdulmohsen M.
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (01): : 315 - 319
  • [39] Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL)
    Nedomova, Radka
    Papajik, Tomas
    Prochazka, Vit
    Indrak, Karel
    Jarosova, Marie
    BIOMEDICAL PAPERS-OLOMOUC, 2013, 157 (03): : 239 - 247
  • [40] The case of a diffuse large B-cell lymphoma (DLBCL) in a course of HIV
    Czepiel, Jacek
    Kluba-Wojewoda, Urszula
    Biesiada, Grazyna
    Mach, Tomasz
    Garlicki, Aleksander
    HIV & AIDS REVIEW, 2010, 9 (01): : 22 - 25